An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Required: MS4A1 overexpression (CD20+)

Confirmed by pathology to have CD20+ relapsed or refractory B-cell non-Hodgkin's lymphoma

Must have received: CD20-targeted therapy — second-line or later

must have received CD20-targeted drugs [excluding CD20-negative tumors]

Must have received: anthracycline — second-line or later

must have received...anthracycline drugs

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: within 3 months before lymphodepletion

Received autologous hematopoietic stem cell transplantation or other autologous cell therapy products within 3 months before lymphodepletion

Cannot have received: allogeneic hematopoietic stem cell transplantation

Exception: within 6 months before lymphodepletion

received allogeneic hematopoietic stem cell transplantation or other allogeneic cell therapy products within 6 months before lymphodepletion

Cannot have received: other organ transplant

subjects who have undergone other organ transplants

Cannot have received: anti-tumor drug treatment

Exception: within 4 weeks before lymphodepletion or within 5 half-lives (whichever is shorter)

Received anti-tumor drug treatment or participated in other interventional clinical studies within 4 weeks before lymphodepletion or within 5 half-lives (whichever is shorter), including but not limited to chemotherapy drugs, small molecule targeted drugs, monoclonal antibodies, antibody-drug conjugates, etc.